# The First Bilateral Staged Oxford Cementless Unicompartmental Knee Arthroplasty in Louisiana Following FDA Approval: A Case Report

## TL;DR

A 63-year-old woman underwent the first staged bilateral cementless Oxford unicompartmental knee surgery in Louisiana, showing rapid recovery and pain relief.

## Contribution

This is the first reported case of staged bilateral cementless Oxford unicompartmental knee arthroplasty in Louisiana following FDA approval.

## Key findings

- The patient experienced rapid recovery and near-complete pain resolution after the right unicompartmental knee surgery.
- Postoperative imaging confirmed proper implant positioning and no complications bilaterally.
- The patient resumed full ambulation and regained functional capacity after both surgeries.

## Abstract

We present the case of a 63-year-old woman with bilateral medial compartment osteoarthritis who underwent the first staged bilateral cementless Oxford unicompartmental knee arthroplasty (OUKA) performed in the state of Louisiana shortly after its FDA approval in 2024. The patient had a five-year history of progressively worsening knee pain refractory to conservative therapy, including corticosteroid injections and physical therapy. Imaging confirmed isolated medial compartment disease with preserved lateral compartments and intact cruciate ligaments. Following the right OUKA, she demonstrated rapid recovery, full extension, and near-complete resolution of pain within four weeks. Due to persistent pain in the contralateral knee, a left OUKA was performed six weeks later with similarly favorable results. Postoperative imaging confirmed appropriate prosthesis positioning bilaterally without evidence of loosening, migration, or malalignment. The patient resumed full ambulation and reported restoration of functional capacity. This case highlights the early postoperative benefits and potential long-term promise of cementless OUKA, including faster recovery, reduced surgical time, and avoidance of cement-related complications. The implant’s titanium and hydroxyapatite coating may further enhance biological fixation and durability. As cementless technology gains traction in the United States, continued follow-up and longitudinal studies will be essential to confirm its long-term survivorship and clinical efficacy compared to traditional cemented designs.